Spyre Therapeutics is building a long-acting antibody platform across IBD and rheumatology. However,

Spyre Therapeutics  SYRE has given investors a classic biotech dilemma. The pipeline is advancing, t

Spyre Therapeutics  SYRE has become a closely watched clinical-stage biotech stock as investors look

SYRE is targeting major IBD drug trends with long-acting antibodies and combination therapies, but i

Spyre is building a modular immunology platform targeting IBD and rheumatic diseases with internally

After a sweeping semi-annual rebalance, the biotech index underlying the ALPS Medical Breakthroughs

Spyre Therapeutics falls 12% amid major insider stock sales. Explore the technical data and market s

U.S. stock futures mixed, Nasdaq 100 up 100 points. FedEx falls after Q4 results, beating estimates

Leifras Co Ltd (NASDAQ: LFS) rose in pre-market trading after acquiring SWIFT JAPAN for JPY454.6 mil

Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 40.3% to $4.56 during Tuesday's after-m

Deutsche Bank analyst David Hoang maintains Spyre Therapeutics (NASDAQ:SYRE) with a Buy and raise

SAGTEC GLOBAL (NASDAQ: SAGT) gained 75.6% in pre-market trading after projecting 35% revenue growth

Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company committed to develop

Top Wall Street analysts updated ratings on CRWD, OLLI, XPO, SHAK, UNH, PVH, VVOS, and SYRE. See ana

Deutsche Bank analyst David Hoang maintains Spyre Therapeutics (NASDAQ:SYRE) with a Buy and raise

Dow falls 296 points. Navitas Semi rises on partnership with Nvidia. Other gainers: ABVX, MMED, KELY

Enrollment for psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) sub-studies of the SKYW

On May 29, 2026, the Company entered into the First Amendment to Amended and Restated License Agreem